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Abstract
Background and Aims: GLI1 is the key transcriptional factor in the Hedgehog signaling pathway in pancreatic cancer. RegIV
is associated with regeneration, and cell growth, survival, adhesion and resistance to apoptosis. We aimed to study RegIV
expression in pancreatic cancer and its relationship to GLI1.
Methods: GLI1 and RegIV expression were evaluated in tumor tissue and adjacent normal tissues of pancreatic cancer
patients and 5 pancreatic cancer cell lines by qRT-PCR, Western blot, and immunohistochemistry (IHC), and the correlation
between them. The GLI1-shRNA lentiviral vector was constructed and transfected into PANC-1, and lentiviral vector
containing the GLI1 expression sequence was constructed and transfected into BxPC-3. GLI1 and RegIV expression were
evaluated by qRT-PCR and Western blot. Finally we demonstrated RegIV to be the target of GLI1 by chromatin
immunoprecipitation (CHIP) and electrophoretic mobility shift assays (EMSA).
Results: The results of IHC and qRT-PCR showed that RegIV and GLI1 expression was higher in pancreatic cancer tissues
versus adjacent normal tissues (p,0.001). RegIV expression correlated with GLI1 expression in these tissues (R=0.795,
p,0.0001). These results were verified for protein (R=0.939, p=0.018) and mRNA expression (R=0.959, p=0.011) in 5
pancreatic cancer cell lines. RegIV mRNA and protein expression was decreased (94.760.3%, 84.160.5%; respectively) when
GLI1 was knocked down (82.163.2%, 76.762.2%; respectively) by the RNAi technique. GLI1 overexpression in mRNA and
protein level (924.565.3%, 362.163.5%; respectively) induced RegIV overexpression (729.164.3%, 339.063.7%;
respectively). Moreover, CHIP and EMSA assays showed GLI1 protein bound to RegIV promotor regions (GATCATCCA) in
pancreatic cancer cells.
Conclusion: GLI1 promotes RegIV transcription by binding to the RegIV gene promoter in pancreatic cancer.
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Introduction
Pancreatic cancer (PC) is the fourth most common cancer-
related cause of mortality in the Western world [1–3] and has a
dismal prognosis despite considerable progress in management.
The median survival of PC is less than 6 months; the 5-year
survival rate is less than 5% [1,2]. More than 80% present with
unresectable disease; one-third have local disease while the
remainder have distant metastases. Research over the last two
decades has shown that PC is a genetic disease fundamentally,
caused by inherited germline and acquired somatic mutations in
cancer-associated genes. Tumor progression model for PC in
which the pancreatic ductal epithelium progresses from normal to
increased grades of pancreatic intraepithelial neoplasia (PanINs) to
invasive cancer. Multiple alterations in genes that are important in
PC progression have been identified, for example K-ras, INK4A,
p53, and SMAD4/DPC4 [4,5]. PC is characterized by near-
universal mutations in K-ras and frequent deregulation of crucial
embryonic signalling pathways, including the Hedgehog (HH)
signaling pathway [6,7]. A better understanding of the mecha-
nisms underlying the development of PC might help to improve
early diagnosis and potentially identify molecular therapeutic
targets.
The hedgehog (HH) signaling pathway was first identified in the
embryonic development of Drosophila [8] and has been shown to
be crucial for growth and patterning in the pancreas during
embryonic development. HH signaling regulates cell differentia-
tion and organ formation during embryonic development , and is
expressed in pancreatic epithelial cells [9,10]. Constitutive
activation of HH signaling is detected in a variety of human
cancers, including pancreatic cancer [9–13]. Given its misexpres-
sion in both metastatic pancreatic cancer cell lines and in
precursor lesions (PanIN) [14], HH signal activation may be
involved in both early and late pancreatic tumorigenesis.
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(SHH), Desert (DHH), and Indian (IHH) Hedgehog [15], the
former has been associated with both pancreatic organogenesis
and pancreatic cancer. HH signals are transmitted and modified
by two transmembrane proteins, patched (PTCH) and smooth-
ened (SMO), and by downstream transcription factors that are
members of the glioma-associated oncogene (GLI) family (GLI1, 2,
and 3). GLI2 and GLI3 have transactivation and repressive
domains, whereas GLI1 likely functions only as a transactivator
and transcriptional target of the HH pathway itself [16–19]. The
regenerating gene (Reg) family, a group of small secretory
proteins, is involved in cell proliferation or differentiation in
digestive organs [20], is upregulated in several gastrointestinal
cancers, and functions as trophic or antiapoptotic factors [21–23].
RegIV, a member of the regenerating gene family, is involved in
digestive tract malignancies, including the stomach [24], color-
ectum [25,26], and pancreas [27,28], as well as in benign diseases
such as ulcerative colitis [29]. RegIV overexpression in tumor cells
has been associated with cell growth, survival, adhesion, and
resistance to apoptosis. Recently, RegIV overexpression was
reported to be associated with the initiation and progression of
pancreatic cancer, and was suggested as a promising tumor
marker to screen early stage PC and target for adjuvant therapy in
PC [28,30].
The functions of GLI1 and RegIV appeared to be similar in our
review of the literature; thus, we investigated the expression and
correlation of GLI1 and RegIV in PC tissues and cell lines. We
also explored the possible mechanism between GLI1 and RegIV,
by using ChIP and EMSA assays.
Materials and Methods
Cell lines and tissues
Human pancreatic cancer cell lines, PANC-1, AsPC-1, BxPC-
3, CaPan-2 and SW1990, were purchased from Chinese
Academy of Sciences Committee Type Culture Collection cell
bank. PANC-1 was cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Gibco BRL, USA), the other types of Cells
were cultured in RPMI-1640 (Gibco BRL, USA), and all the
mediums were supplemented with 10% FBS (Gibco BRL, USA),
penicillin G (100 U/ml), streptomycin (100 ug/ml). Cells were
incubated at 37uC with 5% CO2. Twelve pairs of PC and
corresponding non-cancerous pancreas tissues were obtained
from Shanghai Tenth People’s Hospital with full written ethical
consent. None of these patients had received chemotherapy or
radiation therapy prior to cancer resection. Another 9 paired
tissues slices was obtained from pathology department of
Shanghai Tenth People’s Hospital. The study was approved by
the Ethical Committee of Tongji University School of Medicine
and Life Sciences.
Short Hairpin RNA (shRNA) Design and Vector Production
Interfering sequences corresponding to distinct regions of
GLI1mRNA, as well as negative control with no homology for
human or mouse genes were designed by Shanghai GeneChem
Biotech (Table 1). Three siRNA duplexes were screened for GLI1
knock-down by Western blot analysis in cotransfection experi-
ments with GLI1 expression plasmid in HEK 293T cells. The
most successful sequence and one non-silencing Luciferase
sequence were designed into a shRNA oligonucleotide template
consisting of sense, hairpin loop, antisense, and terminator
sequences, all of which were flanked by restriction enzyme sites
to facilitate directional sub-cloning. The resulting vectors encoded
GFP under transcriptional control of the EF1 promoter and a H1
promoter upstream of cloning restriction sites (MluI and ClaI) to
allow the introduction of oligonucleotides encoding shRNAs.
Either shRNA against GLI1 or a nonsilencing-Luciferase shRNA
was located under the H1 promoter (Figure 1). The correct
insertion of the specific shRNA was further confirmed by direct
DNA sequencing.
For production of the lentiviral vector, HEK 293T cells were
cultured to 30–40% confluence by the following day. The next
day, the medium was replaced with DMEM/10% FBS without
antibiotics. Subsequently, 20 mg of shRNA plasmid DNA
(nonsense shRNA or GLI1 targeting shRNA; GeneChem Biotech,
Shanghai, China), 7.5 mg pMD2G, 10 mg pRsv-Rev, and 15 mg
pMDLg-pRRE were mixed with sterile ddH2O to a final volume
of 1800 ml, then mixed with 200 ml of 2.5 M CaCl2. The DNA
mix was oxygenated and 2000 ml2 6PBS (pH 7.05) added in
drops, and incubated at room temperature for 30 minutes. The
transfection mixture was added to its respective plates and
incubated overnight. The medium was replaced after 12 hours
with DMEM supplemented with 10% FBS. After 48 hours, the
conditioned medium containing shRNA lentivirus was collected
and filtered through 0.45-mm pore size cellulose acetate filters, and
stored on ice. The virus was concentrated by spinning at 70,000 G
for 2 hours and resuspended with 500 ml PBS. The transduction
unit (TU) titer was assessed on HEK 293T cells in the presence of
polybrene 8 mg/mL (Sigma-Aldrich, St. Louis, MO, USA). Titers
of 2–5610
8 TU/ml were routinely achieved.
Overexpression-GLI1 Lentiviral Vector Construction
Human GLI1 cDNA was purchased from Open-Biosystem
(USA). The complete cDNA sequence of GLI1 was generated by
Table 1. Sequences of primers used in this study for GLI1-shRNA constructs.
5’ STEMP Loop STEMP
shGLI1-1 CGCGTCCCC CTCCACAGGCATACAGGAT TTCAAGAGA ATCCTGTATGCCTGTGGAG
CGATTTCCAAAAA CTCCACAGGCATACAGGAT TCTCTTGAA ATCCTGTATGCCTGTGGAG
shGLI1-2 CGCGTCCCC CGTGAGCCTGAATCTGTGTAT TTCAAGAGA ATACACAGATTCAGGCTCACG
CGATTTCCAAAAA CGTGAGCCTGAATCTGTGTAT TCTCTTGAA ATACACAGATTCAGGCTCACG
shGLI1-3 CGCGTCCCC GCTCAGCTTGTGTGTAATTAT TTCAAGAGA ATAATTACACACAAGCTGAGC
CGATTTCCAAAAA GCTCAGCTTGTGTGTAATTAT TCTCTTGAA ATAATTACACACAAGCTGAGC
scramble CGCGTCCCC GCCAGCGTTAACCAGACTA TTCAAGAGA TAGTCTGGTTAACGCTGGC
CGATTTCCAAAAA GCCAGCGTTAACCAGACTA TCTCTTGAA TAGTCTGGTTAACGCTGGC
doi:10.1371/journal.pone.0018434.t001
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TACCGGTCGCCACCATGTTCAACTCGATGACCCCAC-39;
and reverse primer, 59-TCATCCTTGTAGTCGCTAGCGG-
CACTAGAGTTGAGGA-39; then inserted into a pGC-FU-
EGFP-3FLAG Vector (GeneChem Company, Shanghai, China).
Transformants were analyzed by sequencing. The resultant 3320-
bp fragment was confirmed by sequencing (Figure S1) and
compared with the sequence of the GLI1 gene expression region
in GenBank (NM_005269.2). To produce lentiviral stock, 293FT
cells were cultured to 70–85% confluence the following day. The
complete culture medium was removed. Cells were then exposed
to 5 mL medium (Opti-MEM; Invitrogen) with complexes
containing packaging helper construct (GeneChem Company,
Shanghai, China), 20 mg expression plasmid DNA (pGC-FU-
EGFP-3FLAG-GLI1), or control plasmid DNA (pGC-FU-EGFP-
3FLAG) with 100 ml lipofectamine 2000 (Invitrogen, USA) in the
presence of polybrene (8 mg/mL, Sigma-Aldrich, St. Louis, MO,
USA). After incubation for 24 hours, the infection medium was
replaced with complete culture medium. Lentivirus-containing
supernatants were harvested 72 hours after transfection. The
supernatants were centrifuged to remove pellet debris and stored
at 280uC. Titers of 2–5610
7 TU/ml were routinely achieved.
Lentiviral Transfection
Cells (1610
5) in a six-well plate were transfected with the
lentiviral vector at a multiplicity of infection (MOI)=5 (PANC-1)
or 20 (BxPC-3) in the presence of 8 mg/ml polybrene (Sigma-
Aldrich, St. Louis, MO, USA). After 72 hours of transfection, the
medium was replaced with 2 ml complete culture medium.
48 hours after transfection, GLI1 expression was established by
real time-PCR and Western blot analysis.
Flow Cytometry
Cells were adjusted to 1610
6 cells/100 mL and used for flow
cytometry. A total of 10,000 events were analyzed to determine
transfection efficiency using FACS Calibur (Becton Dickinson,
USA) Cell-Quest software.
qRT-PCR
Real-time quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) analysis was performed with the ABI Prism
7900HT Sequence Detection System (Applied Biosystems, CA,
USA). GLI1 and RegIV mRNA expression was analyzed by qRT-
PCR using SYBR Green Dye. b-actin was used as the housekeeping
gene. Target gene expression was normalized to b-actin and
analyzed by the 2
2DDCT formula. The primer sequences are as
follows: GLI1, forward: TTCCTACCAGAGTCCCAAGT,
reverse: CCCTATGTGAAGCCCTATTT, RegIV, forward:
CGCTGAGATGAACCCCAAG, reverse: TGAGAGGGAAGT-
GGGAAGAG. b-actin, forward: AAGGGACTTCCTGTAA-
CAATGCA, reverse: CTGGAACGGTGAAGGTGACA. All re-
actions were performed at least three times.
Western blot analysis
Cells were rinsed twice in PBS, then lysed for 2 hours in RIPA
lysis buffer on ice and centrifuged at 12,000 rpm for 10 minutes at
4uC. Protein concentration was determined by the standard BCA
method (BCA
TM Protein Assay Kit, Pierce, USA). 50 mg of total
protein was separated by SDS-PAGE using 6% or 12%
polyacrylamide gel with Mini-PROTEAN Tetra Cell (Bio-Rad,
USA). GLI1 and RegIV protein in gel was transferred to a 0.45-
mm nitrocellulose membrane with Mini Transfer Cell and Trans-
blot SD Semi-Dry Transfer Cell (Bio-Rad, USA) respectively.
The immunoreagents used for Western blot were rabbit
monoclonal antibody against GLI1 (1:200; Santa Cruz, USA)
and goat polyclonal anti-RegIV antibody (1:100; Santa Cruz,
USA). Mouse polyclonal anti-b-actin antibody (1:5000; Santa
Cruz, USA) was used as loading control. The blots were developed
by a standard enhanced chemiluminescence (ECL) method
(Pierce, USA). All experiments were repeated several times and
gave similar results.
Immunohistochemistry
Tumor sections were deparaffinized, rehydrated, and treated
with 10 mM citrate buffer (pH 6.0) at 95uC to retrieve antigens.
Figure 1. Construction of the pLVTHM vector encoding anti-GLI1 shRNA. For the GLI1-shRNA vector, two single strand DNAs encoding two
linkers, the target sequences and a loop element, were synthesized. These were annealed to double stranded DNA, and ligated into the pLVTHM
following MluI and CalI digestion. The short hairpin form of shGLI1 is expressed under the control of human H1 promoter. The vector also contains a
human EF1-a promoter driving the GFP marker gene for tracking transduced cells. The vectors were generated by transient transfection of pRsv-REV,
pMDlg-pRRE, pMD2G, and the shRNA encoding pLVTHM into 293T cells. Abbreviations: RRE, Rev response element; cPPT, central polypurine tract;
EF1-a, human elongation factor 1-a promoter; H1, the human H1 promoter; GFP, green fluorescent protein; PRE, human hepatitis virus
posttranscriptional regulatory element.
doi:10.1371/journal.pone.0018434.g001
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blocking with 10% normal horse serum, the sections were
incubated sequentially with the primary antibodies goat anti-
RegIV (1:100; Santa Cruz, California, USA), rabbit anti-GLI1
(1:200; Santa Cruz, California, USA), biotinylated secondary
antibodies, and the ABC reagent (Gene Tech, Shanghai, China).
The immunostaining was visualized with 3.3-diaminobenzidine
(Gene Tech, Shanghai, China). The sections were then counter-
stained with hematoxylin. Negative controls were performed in
each case by replacing the primary antibody with PBS.
Chromatin immunoprecipitation (CHIP)
We modified the previously reported protocol [31] for
chromatin immunoprecipitation (CHIP). In brief, PANC-1 cells
(3610
7) were cross-linked with 1% formaldehyde. The fixation
reaction was stopped by adding 10 ml Glycin (0.125 M), then
chromatin was collected with 1 mL IP buffer containing protease
inhibitor cocktails. Chromatin was sheared by using a sonicator
with a 4 mm tip probe 3 times for 10 second pulses (60 W, 80 W,
and 100 W, respectively, 90 s intervals) in an ice box. Crosslinking
was reversed by adding 20 mL of 5 M NaCl overnight at 65uC.
DNA was extracted using phenol/chloroform assay. 20 mLo f
DNA was electrophoresed on a 1.5% agarose gel and the rest was
preserved at 220uC as INPUT DNA. Soluble chromatin was
immunoprecipitated with 2 mg anti-GLI1 rabbit monoclonal
antibody (Santa Cruz, California, USA). The 2 mg mouse IgG
(Santa Cruz, California, USA) was added as a random control,
RNA polymerase II as a positive control, and b-actin antibody as a
negative control. DNA-protein immune complexes were eluted
and reverse cross-linked, and DNA was extracted with phenol/
chloroform and precipitated. The presence of the RegIV promoter
domain containing GLI1 motifs in immunoprecipitated DNA was
identified by PCR using the following primers: RegIV-A for site 1
(118 bp), forward: 59-5-TGGTCCCTTCCAGACTTA-3-39, re-
verse: 59- TCCAGTATAGATGGCAAA -39. RegIV-B for site 2
(131 bp), forward: 59-CTAACCCTTTGCCATCTA -39, reverse:
59-GACCTGGACACTGAACCTTG-39. RegIV-C for site 3
(70 bp), forward: 59-CTATGCTGCTCACAAGGA-39, reverse:
59-GTGTTACATAACGGGTTT-39. RegIV-D for site4 (70 bp),
forward: 59-TGTAACACACTCTGTTGATGTAAGC-39, re-
verse: 59- CTATTTGAGCTTCTCCCGCAG-39. RegIV-E for
sites 3 and 4 (226 bp), forward: 59-CTCGGAAGGTTTC-
TAATC-39, reverse: 59- TTCAACATGCGTGAGTTT-39. Re-
gIV-F for sites 3 and 4 (481 bp), forward: 59-CTATGCTGCT-
CACAAGGA-39, reverse: 59-AGACGGCTTCAGAATGTA-39.
RegIV-G for site 5 (315 bp), forward: 59-TTCCTGAGGCAA-
GAAGAT-39, reverse: 59-CCAAGATTTAACCCAACA-39. The
PCR conditions for the RegIV promoter region were: denatur-
ation 30 seconds at 94uC, annealing 30 s, elongation 1 minute at
72uC. Annealing temperatures for RegIV-A-G were 55uC, 56uC,
56uC, 47uC, 56uC, 56uC, and 52uC, respectively. The amplifica-
tion of the RegIV promoter region was analyzed after 35 cycles.
All experiments were repeated at least three times.
Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts were prepared with NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Pierce, Rockford, USA). EMSA
and supershift EMSA with digoxin-labeled probes were per-
formed using the DIG-Gel shift kit according to the manufac-
turer’s instructions (Roche, Basel, Switzerland). The sequences
of the oligonucleotides used were 59-AGAACATGGATGAT-
CATGTCA-39 (binding motif underlined). Mutant oligonucleotides
used were 59-AGAACAAAAAATTTTATGTCA-39. In the super-
shift study, 5 mg rabbit monoclonal antibody against GLI1 was
incubated with 5 mg of nuclear extract on ice for 30 minutes before
addition of the labeled probe, and further incubated on ice for
30 minutes. Theentire 20 ml bindingreaction wasresolved on a 7%
polyacrylamide gel and transferred to a positively charged nylon
membrane (Bio-Rad, USA) in 0.56Tris borate-EDTA buffer.
Statistical analysis
Quantitative data are expressed as the mean 6 standard
deviation (SD). Real-time PCR data was analyzed according to the
differences of target gene expression by the paired t-test and were
2
2DDCT transformed before analysis. The relationship between
GLI1 and RegIV expression was analyzed using Spearman. IHC
data was analyzed using the Chi-squared test. A p-value of less
than 0.05 was considered statistically significant.
Results
GLI1 and RegIV expression in pancreatic cancer tissues
To study GLI1 and RegIV expression in PC, qRT-PCR and
IHC were used in 12 paired biopsy tissues. GLI1 expression was
higher in 9 cases (9/12) compared with adjacent normal
pancreatic tissues (p=0.011; Figure 2); RegIV expression was
higher in 9 cases (9/12) (p=0.011; Figure 2). There was a positive
correlation between GLI1 and RegIV in PC tissues (R=0.795,
p,0.0001; Figure 2). On IHC, we found RegIV to be expressed
only in beta cells of normal endocrine pancreatic tissues, which
confirmed Oue’s report [37]. On IHC, GLI1 and RegIV
expression were higher in most PC compared with normal tissues
(15/21 versus 4/21, p=0.001; 14/21 versus 5/21, p=0.005;
respectively; Figure 3). 15 of 21 PC cases had high expression of
GLI1 protein, among which 11 cases expressed high levels of
RegIV protein (p=0.001; Figure 3).
The correlation between GLI1 and RegIV
Wetested GLI1and RegIV expression in5 PCcelllinesbyqPCR
and Western blot. There was a positive correlation between the level
of GLI1 and RegIV mRNA and protein (R=0.958, p=0.011 and
R=0.939, p=0.018, respectively; Figure 4). GLI1 and RegIV were
overexpressed in PC versus normal pancreatic cells.
RegIV expression changed with GLI1 expression in PANC-
1 and BxPC-3
To further verify the relationship between GLI1 and RegIV in
PC cells, we designed and constructed shRNA-GLI1 lentiviral
vector, and transfected it into PANC-1, a PC cell line with the
highest expression of GLI1 (Figure 4). 48 hours after transfection,
efficiency of transfection was shown by flow cytometry (FCM) to
be more than 95% (Figure S2); stable fluorescence could still be
detected even after 20 passages (Figure S3).
Afterwards, qRT-PCR and Western blot were used to detect
RegIV expression in GLI1-shRNA-PANC-1 cells. Cells without
transfection were used as controls, while cells transfected with
scramble shRNA were used as negative controls. RegIV mRNA
decreased by 94.760.3% when GLI1 mRNA decreased by
82.163.2%. RegIV protein decreased by 84.160.5% when GLI1
protein decreased by 76.762.2% (Figure 5). This suggested that
RegIV expression decreased when GLI1 was silenced by RNAi.
We further designed and constructed a lentivirus vector that
expressed GLI1, and transfected it into BxPC-3, with the lowest
GLI1 expression in the 5 cell lines (Figure 4), to determine whether
RegIV expression changed along with GLI1. 48 hours after
transfection, qRT-PCR and Western blot were used to detect
RegIV in the LV-GLI1-BxPC-3 cells. Cells without transfection
were used as controls, while cells transfected with empty lentivirus
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729.164.3% when GLI1 mRNA increased by 924.565.3%.
RegIV protein increased by 339.063.7% when GLI1 protein
increased by 362.163.5% (Figure 5). This implies that RegIV
expression increased when GLI1 was overexpressed. Based on
these results, we concluded that GLI1, a transcription factor,
might regulate RegIV gene expression.
Identification of candidate Gli1 binding sites in the RegIV
promoter
The positive correlation between GLI1 and RegIV in both PC
tissue and cell lines prompted us to search the RegIV promoter for
potential GLI1 binding sites to the DNA consensus sequence 59-
GACCACCCA-39 [42]. Database analysis revealed four potential
sites located upstream of the transcriptional start site (Figure 6). The
homology of each GLI1 binding site to the canonical consensus
sequence variedfrom 67% (sites1, 2,3, and 5) to 78%(site 4),which
suggested that the RegIV gene promoter might bind to GLI1.
Confirmation of GLI1 protein bound to promoter region
of RegIV gene by CHIP
The sonicated chromatin solution assay showed that the total
DNA fragment appeared smeared in the 100 bp to 1 kb range in
the 80 W group (Figure S4). The result of DNA electrophoresis
Figure 2. GLI1 and RegIV mRNA expression in PC tissues and adjacent normal tissues. The expression of GLI1 RegIV mRNA in 12 pairs of
PC tissues and adjacent normal tissues(A–B). DNA from the samples were collected from surgical biopsies, and relative GLI1 and RegIV mRNA
expression were detected by qRT-PCR. Statistical correlation between the expression of GLI1 and RegIV mRNA in 12 pairs of PC tissues and adjacent
normal tissues was analyzed by Spearman’s test (C). All results were normalized to b-actin mRNA expression. The data are presented as the mean 6
SD and were calculated by the paired t-test. Significantly different between two groups: *p,0.05. ** p,0.01. NS: not significant.
doi:10.1371/journal.pone.0018434.g002
Figure 3. Expression of GLI1 and RegIV proteins was analyzed by IHC in PC and adjacent normal tissues. All samples were collected,
formalin-fixed, paraffin-embedded, and detected by IHC. Representative pictures are shown. Positive staining of GLI1 was observed at the PDAC cell
nucleus (A); however, adjacent normal tissues exhibited no or faint staining for GLI1 (B). In adjacent normal pancreatic tissues, only islet cells showed
positive staining of RegIV (D), while the positive staining of RegIV was observed as well as goblet-like cytoplasm granules in PC tissues (C). All
photomicrographs were obtained at 6200 magnification. Scale bars, 100 mm.
doi:10.1371/journal.pone.0018434.g003
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postive control groups using human RegIV primer-D-F, and not
in the IgG and negative control groups (Figure 7). Only INPUT
and the positive control showed the predicted band using human
RegIV primer-A-C, G but not in GLI-Ab, IgG, and negative
groups (data not shown). The results of sequence analysis showed
that the sequences were the same as that of the RegIV gene
promoter of site 4 (Figure S5, S6, S7). All data suggested that
GLI1 was bound to the RegIV gene promoter of site 4
(GATCATCCA), and regulated RegIV in PC through the HH
signaling pathway.
Confirmation of GLI1 bound to the RegIV promoter by
EMSA
As described above, the GLI1 binding site in the promoter
region of the RegIV gene was confirmed with ChIP-PCR. We
Figure 4. The expression of GLI1 and RegIV in 5 PC cell lines. Expression of GLI1 and RegIV proteins in 5 pancreatic cancer cell lines as
detected by Western blot analysis on cell extracts, using anti-GLI1 and anti-RegIV antibodies (A). b-actin was used as the loading control in all
experiments. The results were quantified by determining the intensities of the bands compared with that of b-actin (B). Statistical correlation
between expression of GLI1 and RegIV protein in 5 PC cell lines was analyzed by Pearson’s test (C). Relative GLI1 and RegIV mRNA expression were
examined by qRT-PCR (D). The expression of GLI1 and RegIV mRNA was normalized to b-actin mRNA expression. Statistical correlation between the
expression of GLI1 and RegIV mRNA in 5 PC cell lines was analyzed by Pearson’s test (E). All data are presented as the mean 6 SD of three
independent experiments.
doi:10.1371/journal.pone.0018434.g004
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RegIV in vivo. We synthesized specific oligonucleotides containing
the GLI1 element present in the RegIV promoter in EMSA
experiments with nuclear extracts from PANC-1 cell lines. As
shown in Figure 8, incubation of PANC-1 cells extracts with the
biotin-labeled GLI1-RegIV sequence produced a DNA-protein
band shift. These DNA-protein complexes were specific to the
GLI1 site by successful competition assays using different folds of
excess unlabeled GLI1-RegIV and mutant labeled GLI1-RegIV
oligonucleotides. To confirm the binding of GLI1 to the GLI1-
RegIV sequence, these EMSA reactions were further incubated
with anti-GLI1 antibody. As shown in Figure 8, the addition of this
antibody resulted in a supershifted complex in addition to the
DNA-protein band. These data demonstrated the presence of
GLI1 in the nuclear protein complex that binds the GLI1 binding
site of the RegIV promoter (2528,2520).
Discussion
In this study, we confirmed that GLI1 and RegIV were
overexpressed in PC tissue and cell lines, confirmed by other
reports [12,20,32]. We also demonstrated a significantly positive
correlation between the expression of GLI1 and RegIV. RNA
interference and overexpression experiments showed that RegIV
expression changed with GLI1 expression in PC cell lines;
this was confirmed by CHIP and EMSA. This is the first report
Figure 5. RegIV expression changed with GLI1 in PC cells. PANC-1 cells were transfected with GLI1-shRNA or GFP-shRNA, BxPC-3 cells were
transfected with LV-GLI1-eGFP or LV-eGFP, then expression of GLI1 mRNA relative to that of b-actin mRNA was assessed by qRT-PCR (A, D). After
transfection, expression of GLI1 proteins was analyzed by Western blot (C, F). The inset shows a substantial decrease in RegIV expression by real-time
RT-PCT (B, E) and Western blot analysis (C, F). The results were normalized to that of b-actin expression. All data are presented as the mean 6 SD of
three independent experiments.
doi:10.1371/journal.pone.0018434.g005
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RegIV gene promoter, and that GLI1 is a RegIV transcriptional
factor.
The HH signaling pathway, including transcription factor
GLI1, is involved in the development of many kinds of cancers,
including PC [12,13,32–35]; however, the mechanism has not
been fully elucidated. Thus far, only a few downstream targets of
GLI1 have been identified, including GLI1, PTCH, HHIP,
CCND, Snail, Bcl-2, cyclin D2, FOX-F1, -L1, -M1, Follistatin,
and N-Myc [36]. We demonstrated that the HH-GLI1 signaling
pathway could regulate RegIV expression by a serie of
experiments, including CHIP and EMSA. In our literature
review, we learned that RegIV expression in different cell types
was associated with regeneration, and cell growth, survival,
adhesion, and resistance to apoptosis. RegIV is systematically
overexpressed in stomach [24], colon [25,26], and pancreas
cancers [27,28] and in diseases that predispose to colon cancer
such as ulcerative colitis [29]. IHC analysis has confirmed RegIV
expression in gastric, colorectal, and pancreatic carcinoma
[27,37,38], and that RegIV has a potential role in diagnosing
digestive tract neuroendocrine tumors [39]. RegIV gene
amplification is an early event in pancreatic cancer development
[30], and elevated RegIV was found in the sera of patients with
PC [28]. PC-derived cells overexpressing RegIV protein grew
more rapidly and were more resistant to gemcitabine treatment
[30]. RegIV overexpression was thought to be associated with an
unfavorable response to adjuvant chemoradiotherapy in patients
with PC [40]. Other studies showed that RegIV was associated
with a relatively favorable prognosis in patients with gallbladder
carcinoma after surgical resection [41]. Thus, we concluded that
the HH/GLI1/RegIV cascade may be an important pathway in
PC development.
Chromatin immunoprecipitation (CHIP) is a reliable procedure
used to determine whether a protein binds to or is localized to a
specific DNA sequence in vivo. Through CHIP and promoter
analysis, we identified a direct transcriptional target gene of GLI1,
although the GLI1-binding element (GATCATCCA) showed a 2
nucleotide difference (underlined) from a previously identified 9-
nucleotide GLI1-binding sequence (GACCACCCA) [42]. EMSA
is one of the most sensitive methods for studyting protein-DNA
interactions. This procedure can determine if a protein or mixture
of proteins is capable of binding to a given DNA sequence.
‘‘Supershift assay’’ is a term used to unambiguously identify a
protein present in the protein-nucleic acid complex. The EMSA
and supershift assay also confirmed GLI1 to be bound on site 4 of
the RegIV promoter motif. Those results suggested that GLI1 can
bind to RegIV gene promoters on site 4 in vivo. Based on these
results, we concluded that GLI1 transcriptionally regulates RegIV
gene in PC cells.
Although the biological function of RegIV is poorly understood,
it has been reported that RegIV may function as a growth and
antiapoptotic factor in gastric, colon, and pancreatic cancers
[27,29,43,44]. The expression of RegIV may contribute to liver
metastasis through induction of MMP7 by RegIV [44], and is a
Figure 6. Potential GLI1 binding sites on the RegIV promoter
and homology to the GLI1 consensus sequence. (A) Location of
the potential GLI1 binding sites (numbers 1–5) in relation to the
structure of the gene. P represents the transcriptional start site. The
gray frame represents the variable splicing site. Blank frames represent
exons. (B) Position of the binding sites on the promoter in relation to
the P transcriptional start site and the sequence homology to the GLI1
consensus binding sequence, GACCACCCA.
doi:10.1371/journal.pone.0018434.g006
Figure 7. Modulation of GLI1 binding on RegIV promoter was assessed by Chromatin immunoprecipitation (ChIP) assay. The
locations of RegIV primer-A-G in the promoter region of RegIV gene. The numbers on the schematic of the RegIV gene (numbers 1–5) correspond to
the potential GLI1 binding sites. P represents the transcriptional start site. Lysates from PANC-1 cells were subjected to Chromatin
immunoprecipitation by anti-GLI1 antibody. Human RegIV primer-A-G were used to amplify the RegIV promoter region containing the putative
GLI1-binding site. Sonicated chromatin were used as INPUT DNA control. IgG, RNA polymerase II, and b-actin Ab were used as random controls,
positive controls, and negative controls. (B) Only INPUT, positive control, and GLI1-Ab showed the predicted band in ethidium bromide-stained
agarose gels using the CHIP-PCR products which were amplified by RegIV primer-D(i), RegIV primer-E(ii), and RegIV primer-F(iii). No detectable
transcript was observed in amplified template from IgG or negative control and a positive control lane confirmed the expected fragment. Molecular
weight standards (Marker) were used to estimate the size of the amplified bands.
doi:10.1371/journal.pone.0018434.g007
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colon cancer cells. It also increases the expression of Bcl-2, Bcl-xl,
and survival proteins, all associated with the inhibition of apoptosis
[44]. However, the role of RegIV in migration and invasion, and
whether GLI1 contributes to proliferation, migration, and
invasiveness through RegIV regulation in PC is still unclear.
Whether RegIV is transcriptionally regulated by GLI1, thus
imposing its effect on pancreatic carcinogenesis, the pathways
responsible require further investigation. The coherence of
different molecular events would be partly elucidated by revealing
the mechanism of transcriptional regulation between GLI1 and
RegIV, which may be determined by investigating the effects of
GLI1 and RegIV on common signaling pathways such as the
EGFR/Akt/AP1 cascade, as reported recently both in HH and
RegIV. Our work may contribute to the body of research on
pancreas carcinogenesis and provide insight into the correlated
network of signaling pathways through the GLI1/RegIV axis.
In conclusion, the SHH-GLI1 signaling pathway regulates the
transcription of RegIV gene in PC. This is the first report that
demontrates GLI1 as a transcriptional factor that regulates RegIV
expression in PC. Our work may help to elucidate the molecular
mechanism of the SHH-GLI1 signaling pathway and promote
earlier diagnosis and treatment of PC. The newly identified GLI1/
RegIV axis provides a new insight into PC pathogenesis.
Additional studies are required to determine whether the
biological behavior of GLI1 in PC may be achieved by regulating
RegIV.
Supporting Information
Figure S1 The result of sequence analysis of positive
clone products in overexpression-GLI1 lentiviral vector
construction. The resultant 3320-bp fragment was confirmed by
sequencing which is same with the sequence of the GLI1 gene
expression region in GenBank (NM_005269.2).
(TIF)
Figure S2 Transduction efficiency of PANC-1 cells by
lentivirus vector were evaluated by FCM. Cells were
transfected with GFP-vector. Transduction efficiency based on the
fluorescent signalwas analyzed by FCM. (A) PANC-1 cells without
transfection were used as the blank control; (B) Cells transfected
with GFP-shRNA as random control; (C) Cells transfected with
GLI1-shRNA as experiment group.
(TIF)
Figure S3 Transduction efficiency of PANC-1 cells by
lentivirus vector, phase contrast and GFP expression
under a fluorescent microscope. Transduction efficiency of
PANC-1 cells by GLI1 silencing vector. PANC-1 cells were
transfeced with the GLI1-shRNA vector. The corresponding
phase-contrast image(left panel), the GFP fluorescence (middle
panel) and the merged image (right panel) are shown at a
magnification of 6200. GFP expression reveals high transduction
efficiency, with more than 90% of cells being transduced.
(TIF)
Figure S4 Electropheretogram of sonicated chromatin
solution in different conditions. Sonicated chromatin
solution in different conditions were electrophoresed on 1.5%
agarose gel containing ethidium bromied. DNA sizes appear
smear at a range of 100 bp to 1 kb range in 80 W group.
(TIF)
Figure S5 The result of sequence analysis of CHIP
products which amplified by RegIV primer-D. The result
showed that the sequence amplified with RegIV primer-D is the
same as that of RegIV gene promoter region containing GLI1-
binding site 4.
(TIF)
Figure S6 The result of sequence analysis of CHIP
products which amplified by RegIV primer-E. The result
showed that the sequence amplified with RegIV primer-E is the
same as that of RegIV gene promoter region containing GLI1-
binding site 4.
(TIF)
Figure S7 The result of sequence analysis of CHIP
products which amplified by RegIV primer-F. The result
showed that the sequence amplified with RegIV primer-F is the
same as that of RegIV gene promoter region containing GLI1-
binding site 4.
(TIF)
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